Carcinoma, Squamous Cell of Head and Neck
Oncology
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Cell Therapy
133%
Small Molecule
133%
Monoclonal Antibody
133%
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Innogene KalbiotechSingapore - Singapore
1 program1
NimotuzumabPhase 3Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Innogene KalbiotechNimotuzumab
Boehringer IngelheimAfatinib
Mendusilixadencel
Clinical Trials (3)
Total enrollment: 30 patients across 3 trials
Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer
Start: Aug 2009Est. completion: Jan 2025
Phase 3Unknown
Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck
Start: Jul 2012Est. completion: Aug 201530 patients
Phase 2Completed
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
Start: Jan 2019Est. completion: Dec 2021
Phase 1Terminated
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
1h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
1h ago
Office Administrator
SystImmune
1h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
1h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
1h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
1h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
Cell Therapy is the dominant modality (33% of programs)
3 companies competing in this space